|
1
|
Gobbi PG, Ferreri AJ, Ponzoni M and Levis
A: Hodgkin lymphoma. Crit Rev Oncol Hematol. 85:216–237. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Venkataraman G, Mirza MK, Eichenauer DA
and Diehl V: Current status of prognostication in classical Hodgkin
lymphoma. Br J Haematol. 165:287–299. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Küppers R: The biology of Hodgkin's
lymphoma. Nat Rev Cancer. 9:15–27. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jalali A, Ha FJ, Chong G, Grigg A,
Mckendrick J, Schwarer AP, Doig R, Hamid A and Hawkes EA: Hodgkin
lymphoma: An Australian experience of ABVD chemotherapy in the
modern era. Ann Hematol. 95:809–816. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Meyer RM, Gospodarowicz MK, Connors JM,
Pearcey RG, Wells WA, Winter JN, Horning SJ, Dar AR, Shustik C,
Stewart DA, et al: ABVD alone versus radiation-based therapy in
limited-stage Hodgkin's lymphoma. N Engl J Med. 366:399–408. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Morales CR, Li DL, Pedrozo Z, May HI,
Jiang N, Kyrychenko V, Cho GW, Kim SY, Wang ZV, Rotter D, et al:
Inhibition of class I histone deacetylases blunts cardiac
hypertrophy through TSC2-dependent mTOR repression. Sci Signal.
9:ra342016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Falkenberg KJ and Johnstone RW: Histone
deacetylases and their inhibitors in cancer, neurological diseases
and immune disorders. Nat Rev Drug Discov. 13:673–691. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Phelps MP, Bailey JN, Vleeshouwer-Neumann
T and Chen EY: CRISPR screen identifies the NCOR/HDAC3 complex as a
major suppressor of differentiation in rhabdomyosarcoma. Proc Natl
Acad Sci USA. 113:15090–15095. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Locatelli SL, Cleris L, Stirparo GG,
Tartari S, Saba E, Pierdominici M, Malorni W, Carbone A, Anichini A
and Carlo-Stella C: BIM upregulation and ROS-dependent necroptosis
mediate the antitumor effects of the HDACi Givinostat and Sorafenib
in Hodgkin lymphoma cell line xenografts. Leukemia. 28:1861–1871.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bolden JE, Peart MJ and Johnstone RW:
Anticancer activities of histone deacetylase inhibitors. Nat Rev
Drug Discov. 5:769–784. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Minucci S and Pelicci PG: Histone
deacetylase inhibitors and the promise of epigenetic (and more)
treatments for cancer. Nat Rev Cancer. 6:38–51. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zagni C, Floresta G, Monciino G and
Rescifina A: The search for potent, small-molecule HDACIs in cancer
treatment: A decade after vorinostat. Med Res Rev. 37:1373–1428.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lin TY, Fenger J, Murahari S, Bear MD,
Kulp SK, Wang D, Chen CS, Kisseberth WC and London CA: AR-42, a
novel HDAC inhibitor, exhibits biologic activity against malignant
mast cell lines via down-regulation of constitutively activated
Kit. Blood. 115:4217–4225. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Peart MJ, Smyth GK, van Laar RK, Bowtell
DD, Richon VM, Marks PA, Holloway AJ and Johnstone RW:
Identification and functional significance of genes regulated by
structurally different histone deacetylase inhibitors. Proc Natl
Acad Sci USA. 102:3697–3702. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Batlevi CL, Crump M, Andreadis C, Rizzieri
D, Assouline SE, Fox S, van der Jagt RHC, Copeland A, Potvin D,
Chao R and Younes A: A phase 2 study of mocetinostat, a histone
deacetylase inhibitor, in relapsed or refractory lymphoma. Br J
Haematol. 178:434–441. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jude JG, Spencer GJ, Huang X, Somerville
TDD, Jones DR, Divecha N and Somervaille TCP: A targeted knockdown
screen of genes coding for phosphoinositide modulators identifies
PIP4K2A as required for acute myeloid leukemia cell proliferation
and survival. Oncogene. 34:1253–1262. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kirschbaum MH: Histone deacetylase
inhibitors and Hodgkin's lymphoma. Lancet Oncol. 12:1178–1179.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zagni C, Floresta G, Monciino G and
Rescifina A: The search for potent, small-molecule HDACIs in cancer
treatment: A decade after vorinostat. Med Res Rev. 37:1373–1428.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rosenquist R and Stamatopoulos K: B-cell
malignancies: All roads lead to NF-κB activation. Semin Cancer
Biol. 39:1–2. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Weniger MA and Küppers R: NF-κB
deregulation in Hodgkin lymphoma. Semin Cancer Biol. 39:32–39.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Roemer MGM, Redd R and Cader F: Major
histocompatibility complex class II and programmed death ligand 1
expression predict outcome after programmed death 1 blockade in
classic hodgkin lymphoma. J Clin Oncol. 36:942–950. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tanaka Y, Maeshima AM, Nomoto J, Makita S,
Fukuhara S, Munakata W, Maruyama D, Tobinai K and Kobayashi Y:
Expression pattern of PD-L1 and PD-L2 in classical Hodgkin
lymphoma, primary mediastinal large B-cell lymphoma, and gray zone
lymphoma. Eur J Haematol. 100:511–517. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pianko MJ, Moskowitz AJ and Lesokhin AM:
Immunotherapy of lymphoma and myeloma: Facts and hopes. Clin Cancer
Res. 24:1002–1010. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Alinari L and Blum K: How I treat relapsed
classical Hodgkin lymphoma after autologous stem cell transplant.
Blood. 127:287–295. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Villasboas JC and Ansell S: Checkpoint
inhibition: programmed cell death 1 and programmed cell death 1
ligand inhibitors in Hodgkin lymphoma. Cancer J. 22:17–22. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Huang R, Zhang X, Sophia S, Min Z and Liu
X: Clinicopathological features and prediction values of HDAC1,
HDAC2, HDAC3, and HDAC11 in classical Hodgkin lymphoma. Anticancer
Drugs. 29:364–370. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Delbridge A, Grabow S, Strasser A and Vaux
DL: Thirty years of BCL-2: Translating cell death discoveries into
novel cancer therapies. Nat Rev Cancer. 16:99–109. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Karube K and Campo E: MYC alterations in
diffuse large B-cell lymphomas. Semin Hematol. 52:97–106. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Richmond A: Nf-kappa B, chemokine gene
transcription and tumour growth. Nat Rev Immunol. 2:664–674. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang Y, Tang P, Chen Y, Chen J, Ma R and
Sun L: Overexpression of microRNA-125b inhibits human acute myeloid
leukemia cells invasion, proliferation and promotes cells apoptosis
by targeting NF-κB signaling pathway. Biochem Biophys Res Commun.
488:60–66. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lee SJ, Jung YH, Song EJ, Jang KK, Choi SH
and Han HJ: Vibrio vulnificus VvpE stimulates IL-1β production by
the hypomethylation of the IL-1β promoter and NF-κB activation via
lipid raft-dependent ANXA2 recruitment and reactive oxygen species
signaling in intestinal epithelial cells. J Immunol. 195:2282–2293.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
de Oliveira KA, Kaergel E, Heinig M,
Fontaine JF, Patone G, Muro EM, Mathas S, Hummel M, Andrade-Navarro
MA, Hübner N and Scheidereit C: A roadmap of constitutive NF-κB
activity in Hodgkin lymphoma: Dominant roles of p50 and p52
revealed by genome-wide analyses. Genome Med. 8:282016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Buglio D, Mamidipudi V, Khaskhely NM,
Brady H, Heise C, Besterman J, Martell RE, MacBeth K and Younes A:
The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin
lymphoma cell lines and synergizes with proteasome inhibitors by an
HDAC6-independent mechanism. Br J Haematol. 151:387–396. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang YH, Tian M, Tang MX, Liu ZZ and Liao
AH: Recent insight into the role of the PD-1/PD-L1 pathway in
feto-maternal tolerance and pregnancy. Am J Reprod Immunol.
74:201–208. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Le Burel S, Champiat S, Routier E,
Aspeslagh S, Albiges L, Szwebel TA, Michot JM, Chretien P, Mariette
X, Voisin AL and Lambotte O: Onset of connective tissue disease
following anti-PD1/PD-L1 cancer immunotherapy. Ann Rheum Dis.
77:468–470. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Seko Y, Yagita H, Okumura K, Azuma M and
Nagai R: Roles of programmed death-1 (PD-1)/PD-1 ligands pathway in
the development of murine acute myocarditis caused by
coxsackievirus B3. Cardiovasc Res. 75:158–167. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Topalian SL, Taube JM, Anders RA and
Pardoll DM: Mechanism-driven biomarkers to guide immune checkpoint
blockade in cancer therapy. Nat Rev Cancer. 16:275–287. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
McDermott DF, Huseni MA, Atkins MB, Motzer
RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, et
al: Clinical activity and molecular correlates of response to
atezolizumab alone or in combination with bevacizumab versus
sunitinib in renal cell carcinoma. Nat Med. 24:749–757. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chen XY, Zhang J, Hou LD, Zhang R, Chen W,
Fan HN, Huang YX, Liu H and Zhu JS: Upregulation of PD-L1 predicts
poor prognosis and is associated with miR-191-5p dysregulation in
colon adenocarcinoma. Int J Immunopathol Pharmacol.
32:20587384187903182018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Muro K, Chung HC, Shankaran V, Geva R,
Catenacci D, Gupta S, Eder JP, Golan T, Le DT, Burtness B, et al:
Pembrolizumab for patients with PD-L1-positive advanced gastric
cancer (KEYNOTE-012): A multicentre, open-label, phase 1b trial.
Lancet Oncol. 17:717–726. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Keir ME, Butte MJ, Freeman GJ and Sharpe
AH: PD-1 and its ligands in tolerance and immunity. Annu Rev
Immunol. 26:677–704. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ravi R, Noonan KA, Pham V, Bedi R,
Zhavoronkov A, Ozerov IV, Makarev E, Artemov V A, Wysocki PT, Mehra
R, et al: Bifunctional immune checkpoint-targeted antibody-ligand
traps that simultaneously disable TGFβ enhance the efficacy of
cancer immunotherapy. Nat Commun. 9:7412018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Fife BT, Pauken KE, Eagar TN, Obu T, Wu J,
Tang Q, Azuma M, Krummel MF and Bluestone JA: Interactions between
PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop
signal. Nat Immunol. 10:1185–1192. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lau J, Cheung J, Navarro A, Lianoglou S,
Haley B, Totpal K, Sanders L, Koeppen H, Caplazi P, McBride J, et
al: Tumour and host cell PD-L1 is required to mediate suppression
of anti-tumour immunity in mice. Nat Commun. 8:145722017.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gravelle P, Burroni B, Péricart S, Rossi
C, Bezombes C, Tosolini M, Damotte D, Brousset P, Fournié JJ and
Laurent C: Mechanisms of PD-1/PD-L1 expression and prognostic
relevance in non-Hodgkin lymphoma: A summary of immunohistochemical
studies. Oncotarget. 8:44960–44975. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Buglio D, Mamidipudi V, Khaskhely NM,
Brady H, Heise C, Besterman J, Martell RE, MacBeth K and Younes A:
The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin
lymphoma cell lines and synergizes with proteasome inhibitors by an
HDAC6-independent mechanism. Br J Haematol. 151:387–396. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Booth L, Roberts J, Poklepovic A, Kirkwood
J and Dent P: HDAC inhibitors enhance the immunotherapy response of
melanoma cells. Oncotarget. 8:83155–83170. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Woods DM, Sodré AL, Villagra A, Sarnaik A,
Sotomayor EM and Weber J: HDAC inhibition upregulates PD-1 ligands
in melanoma and augments immunotherapy with PD-1 blockade. Cancer
Immunol Res. 3:1375–1385. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Briere D, Sudhakar N, Woods DM, Hallin J,
Engstrom LD, Aranda R, Chiang H, Sodré AL, Olson P, Weber JS and
Christensen JG: The class I/IV HDAC inhibitor mocetinostat
increases tumor antigen presentation, decreases immune suppressive
cell types and augments checkpoint inhibitor therapy. Cancer
Immunol Immunother. 67:381–392. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Roemer MG, Advani RH, Ligon AH, Natkunam
Y, Redd RA, Homer H, Connelly CF, Sun HH, Daadi SE, Freeman GJ, et
al: PD-L1 and PD-L2 genetic alterations define classical Hodgkin
lymphoma and predict outcome. J Clin Oncol. 34:2690–2697. 2016.
View Article : Google Scholar : PubMed/NCBI
|
